Back to search

Article

A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib

2022-06-16

Abstract excerpt

Patients with chronic myelogenous leukemia (CML) harboring the T315I mutation who progress to blast phase CML while on ponatinib may be successfully treated with asciminib monotherapy following induction therapy with cytotoxic chemotherapy.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a65ef900-7b77-55e9-9a3d-d14cf4952dc8
DOI
10.22541/au.165538265.55890278/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminibDOI 10.22541/au.165538265.55890278/v1
[Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with BCR-ABLT315I Mutation--Review].Semantic proximity
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.Semantic proximity
Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.Semantic proximity
Asciminib in chronic myeloid leukemia.Semantic proximity
Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.Semantic proximity
Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutationsSemantic proximity
Asciminib in the treatment of chronic myeloid leukemia in chronic phase.Semantic proximity
Ponatinib in the therapy of chronic myeloid leukemia.Semantic proximity
A nomogram for predicting T315I-free survival in chronic phase chronic myeloid leukemia patients: a multicenter retrospective studySemantic proximity
Asciminib for chronic myeloid leukaemia: Next questions.Semantic proximity
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.Semantic proximity
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.Semantic proximity
Select a neighboring publication to make it the new centre.